Published in Int J Gynecol Pathol on October 01, 2007
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause (2005) 2.03
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology (2009) 1.91
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res (2005) 1.52
TCTP is an androgen-regulated gene implicated in prostate cancer. PLoS One (2013) 1.45
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol (2007) 1.23
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer (2004) 1.22
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol (2006) 1.21
Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol (2012) 1.16
Concern Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol (2002) 1.10
Retracted Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. J Clin Oncol (2005) 1.09
Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res (2007) 1.07
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer (2005) 1.06
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res (2003) 1.05
Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer (2004) 1.03
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol (2009) 1.00
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer (2007) 0.98
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer (2013) 0.96
Genomic aberrations in borderline ovarian tumors. J Transl Med (2010) 0.95
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer (2008) 0.95
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis (2003) 0.94
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res (2008) 0.94
Cytogenetic characterization of tumors of the vulva and vagina. Genes Chromosomes Cancer (2003) 0.93
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res (2010) 0.93
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia (2003) 0.92
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol (2004) 0.92
Trisomy 7 in postoperative spindle cell nodules. Cancer Genet Cytogenet (2007) 0.92
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat (2004) 0.91
Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol (2006) 0.91
Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution. J Oncol (2009) 0.91
Large scale genomic instability as an additive prognostic marker in early prostate cancer. Cell Oncol (2009) 0.90
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol (2005) 0.90
Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix. Gynecol Oncol (2003) 0.89
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology. Diagn Cytopathol (2002) 0.89
Prognostic value of adaptive textural features--the effect of standardizing nuclear first-order gray level statistics and mixing information from nuclei having different area. Cell Oncol (2006) 0.89
Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer (2009) 0.89
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A (2013) 0.89
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol (2009) 0.89
Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature. Diagn Cytopathol (2005) 0.88
Low dimensional adaptive texture feature vectors from class distance and class difference matrices. IEEE Trans Med Imaging (2004) 0.88
Retracted Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol (2003) 0.87
Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancy. Med Pediatr Oncol (2002) 0.87
PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1. Biochem J (2014) 0.87
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications. Virchows Arch (2009) 0.87
Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters. Eur J Cancer (2009) 0.87
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. Am J Clin Pathol (2009) 0.86
Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev (2013) 0.85
Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol (2005) 0.85
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum Pathol (2006) 0.83
Automatic segmentation of cell nuclei in Feulgen-stained histological sections of prostate cancer and quantitative evaluation of segmentation results. Cytometry A (2012) 0.83
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol (2006) 0.83
Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. Hum Pathol (2011) 0.82
Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. Diagn Cytopathol (2007) 0.82
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens. Int J Gynecol Pathol (2010) 0.81
Genomic profile of ovarian carcinomas. BMC Cancer (2014) 0.81
Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med (2003) 0.81
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol (2005) 0.81
Multiple chromosomal monosomies are characteristic of giant cell ependymoma. Hum Pathol (2011) 0.81
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer (2004) 0.81
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer. Anal Cell Pathol (Amst) (2012) 0.80
The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens. Diagn Cytopathol (2004) 0.80
Nucleoside transporters are widely expressed in ovarian carcinoma effusions. Cancer Chemother Pharmacol (2011) 0.79
NKX3.1 expression is lost in testicular germ cell tumors. Am J Pathol (2003) 0.79
Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc (2008) 0.79
Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol (2005) 0.79
Consistent numerical chromosome aberrations in thecofibromas of the ovary. Virchows Arch (2008) 0.79
The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. Hum Pathol (2006) 0.78
The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. Semin Diagn Pathol (2006) 0.78
Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes. Genes Chromosomes Cancer (2010) 0.78
Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas (2004) 0.78
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas. Cytometry A (2014) 0.78
The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. Breast J (2008) 0.77
The diagnostic and research applications of flow cytometry in cytopathology. Diagn Cytopathol (2012) 0.77
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors. Diagn Cytopathol (2008) 0.77
The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation. Mol Cancer (2005) 0.77
Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls. Cytometry B Clin Cytom (2007) 0.77
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables. Cancer Genet Cytogenet (2004) 0.77
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol (2007) 0.76
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female. Hum Pathol (2003) 0.75
Correction: TCTP is an androgen-regulated gene implicated in prostate cancer. PLoS One (2015) 0.75
A camera support for operating theatre videography. J Vis Commun Med (2012) 0.75
Tidsskr Nor Laegeforen (2017) 0.75
Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling? Scand J Urol (2013) 0.75